Helicos Targets 2011 Launch for Molecular Test for Hereditary Breast, Ovarian Cancer | GenomeWeb

This article was originally published June 25.

About a month after Helicos BioSciences laid off half its workforce to refocus its business on diagnostics, the company said last week that it is in the early stages of developing several molecular diagnostics tests.

Helicos said it will launch a test in the second quarter of 2011 that will identify gene mutations associated with a woman's risk of developing hereditary breast or ovarian cancer. It also plans to develop additional MDx tests such as non-invasive prenatal diagnostic tests.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.